A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...
The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...
Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
A new study is shining a light on a potential way to make treatments work better for one of the deadliest forms of cancer. Researchers at Ohio University have identified a protein that could be a ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If ...
Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results